Yohimbine (Hydrochloride)

Yohimbine hydrochloride is an alpha-2 renal adenomatase receptor inhibitor, blocking pre- and post-contact alpha-2 renal adenomatase receptors, causing the release of renal adenoma and multiple sclerosis.

[1]Docherty JR, et al. Yohimbine antagonises α1A- and α1D-adrenoceptor mediated components in addition to the α2A-adrenoceptor component to pressor responses in the pithed rat. Eur J Pharmacol. 2012 Mar 15;679(1-3):90-4.|[2]Docherty JR. Yohimbine antagonises α1A- and α1D-adrenoceptor mediated components in addition to the α2A-adrenoceptor component to pressor responses in the pithed rat. Eur J Pharmacol. 2012 Mar 15;679(1-3):90-4.|[3]Damase-Michel C, et al. The effect of yohimbine on sympathetic responsiveness in essential hypertension. Eur J Clin Pharmacol. 1993;44(2):199-201.|[4]Musso NR, et al. Yohimbine effects on blood pressure and plasma catecholamines in human hypertension. Am J Hypertens. 1995 Jun;8(6):565-71. |[5]Sáiz J, et al. Yohimbine-induced alterations in alpha(2)-adrenoceptors in kidney regions of the spontaneously hypertensive rats: an autoradiographic analysis. Pharmacol Rep. 2008 May-Jun;60(3):391-8.Eur J Pharmacol. 2023 Nov 6:176174.|Exp Neurobiol. 2020 Oct 31;29(5):356-375.|Mol Biol Rep. 2020 May;47(5):3629-3639.|Mol Med Rep. 2020 Jul;22(1):175-184.|Neurosci Bull. 2022 Apr;38(4):386-402.|Biomed Pharmacother. 2022 Apr 26;150:113006.|Drug Des Devel Ther. 2024 Apr 9:18:1103-1114.|Eur J Neurosci. 2021 Nov 4.|J Neuroinflammation. 2022 May 27;19(1):123.|J Neurophysiol. 2023 Apr 12.|Research Square Preprint. 2023 Dec 16.